Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Tandem Investment Advisors Inc.

Tandem Investment Advisors Inc. cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,177 shares of the company’s stock after selling 3,466 shares during the quarter. Tandem Investment Advisors Inc.’s holdings in Henry Schein were worth $4,102,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in HSIC. Baystate Wealth Management LLC boosted its holdings in Henry Schein by 2,500.0% in the third quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. McGlone Suttner Wealth Management Inc. acquired a new position in Henry Schein in the fourth quarter valued at approximately $39,000. Neo Ivy Capital Management acquired a new position in Henry Schein in the third quarter valued at approximately $46,000. Covestor Ltd boosted its holdings in Henry Schein by 88.4% in the first quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after purchasing an additional 404 shares in the last quarter. Finally, RVW Wealth LLC acquired a new position in Henry Schein in the third quarter valued at approximately $104,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Trading Down 1.4 %

NASDAQ:HSIC traded down $1.02 during mid-day trading on Wednesday, reaching $70.20. The company’s stock had a trading volume of 1,067,027 shares, compared to its average volume of 1,112,613. The company’s fifty day simple moving average is $74.63 and its two-hundred day simple moving average is $72.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $85.39. The stock has a market cap of $9.02 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.75 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to analysts’ expectations of $3 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.21 earnings per share. On average, equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Evercore ISI boosted their price objective on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. Barrington Research boosted their price objective on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a research note on Monday, February 26th. Finally, Piper Sandler boosted their price objective on Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.